P76.70 Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma

Authors :: Joel W. Neal
Sukhmani K. Padda
Heather A. Wakelee
Jacqueline V. Aredo
Source :: Journal of Thoracic Oncology. 16:S619
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
Lung
business.industry
Afatinib
medicine.disease
medicine.anatomical_structure
Internal medicine
medicine
Adenocarcinoma
Osimertinib
In patient
business
medicine.drug

Full Text Access

Tools